Eclipsebio completed the acquisition of Terrain Bio to enhance its end‑to‑end RNA therapeutic platform, combining Terrain’s machine‑learning RNA design capabilities with Eclipsebio’s sequencing‑first analytics. Eclipsebio said the deal will accelerate RNA construct design, structure/translation measurement and manufacturing quality‑by‑design workflows for RNA drug developers. Financial terms were not disclosed. Eclipsebio CEO Peter Chu said the acquisition advances the company’s vision to support iterative RNA design and validation earlier in development. The combined capabilities aim to reduce cycle time from construct ideation to validated, manufacturable RNA assets. Terrain customers will continue to receive support during the transition; Eclipsebio will integrate Terrain’s algorithms into its analytic offerings and provide continuity for ongoing partnerships. The move underscores investor and strategic appetite for platforms that fuse AI design with high‑resolution sequencing validation in the fast‑growing RNA therapeutics market. Buyers of RNA drugs and CMOs may see tighter coupling of design and manufacturing data as a way to de‑risk scale‑up and regulatory filings for next‑generation modalities.